Long-term in-hospital mortality and chronic thromboembolic pulmonary hypertension after COVID-19-associated pulmonary embolism in France: a nationwide study.

Long-term in-hospital mortality and chronic thromboembolic pulmonary hypertension after COVID-19-associated pulmonary embolism in France: a nationwide study.

Publication date: Sep 01, 2025

Although long-term effects of coronavirus disease-2019 (COVID-19) such as dyspnoea are frequent, the mechanisms are often poorly understood. The endothelial effects of COVID-19, such as venous or arterial thrombosis, are also well documented. Thus, the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) following COVID-19 is an issue with many implications, particularly for screening in patients with long COVID. From the French National Hospital Discharge database (March 2020 to December 2021), we included all adults hospitalised for pulmonary embolism (PE). To study the hospital incidence of CTEPH, we excluded patients with previous pulmonary hypertension diagnoses. Then, in the 2 years following the admission for PE, we compared the hospital incidence of CTEPH between PE patients with COVID-19 (COVID-PE) and without (non-COVID-PE). We also studied in-hospital mortality. Among the 136 505 patients included, 1. 68% were diagnosed with CTEPH in the following 2 years with a significant difference between COVID-PE and non-COVID-PE (0. 77% versus 1. 82%; p

Open Access PDF

Concepts Keywords
Coronavirus Associated
December Chronic
French Covid
Hospitalised Cteph
Embolism
Hospital
Hypertension
Incidence
Included
Long
Mortality
Pe
Pulmonary
Term
Thromboembolic

Semantics

Type Source Name
disease MESH pulmonary hypertension
disease MESH COVID-19
disease MESH pulmonary embolism
pathway KEGG Coronavirus disease
disease MESH long COVID

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *